Polak M E, Borthwick N J, Gabriel F G, Johnson P, Higgins B, Hurren J, McCormick D, Jager M J, Cree I A
Translational Oncology Research Centre, Department of Surgery and Histopathology, Queen Alexandra Hospital, Southwick Hill, Portsmouth PO6 3LY, UK.
Br J Cancer. 2007 Jun 18;96(12):1879-87. doi: 10.1038/sj.bjc.6603763. Epub 2007 Jun 12.
Cutaneous melanoma is highly immunogenic, yet primary melanomas and metastases develop successfully in otherwise immunocompetent patients. To investigate the local immunosuppressive microenvironment, we examined the presence of suppressor T lymphocytes and tolerising dendritic cells (DCs), the expression of immunosuppressive cytokines (IL-10, TGFbeta1 and TGFbeta2) and the enzyme indoleamine 2,3-dioxygenase (IDO) using qRT-PCR and immunohistochemistry in primary skin melanomas, negative and positive sentinel lymph nodes (SLN), and lymph nodes with advanced metastases. Our results indicate that tolerogenic DCs and suppressor T lymphocytes are present in melanoma at all stages of disease progression. They express transforming growth factor beta receptor 1 (TGFbetaR1), and are therefore susceptible to TGFbeta1 and TGFbeta2 specifically expressed by primary melanoma. We found that expression of IDO and interleukin 10 (IL-10) increased with melanoma progression, with the highest concentration in positive SLN. We suggest that negative SLN contain immunosuppressive cells and cytokines, due to preconditioning by tolerogenic DCs migrating from the primary melanoma site to the SLN. In primary melanoma, TGFbeta2 is likely to render peripheral DCs tolerogenic, while in lymph nodes IDO and TGFbeta1 may have a major effect. This mechanism of tumour-associated immunosuppression may inhibit the immune response to the tumour and may explain the discrepancy between the induction of systemic immunity by anti-melanoma vaccines and their poor performance in the clinic.
皮肤黑色素瘤具有高度免疫原性,但原发性黑色素瘤和转移灶却能在原本具有免疫能力的患者体内成功发展。为了研究局部免疫抑制微环境,我们使用定量逆转录聚合酶链反应(qRT-PCR)和免疫组织化学方法,检测了原发性皮肤黑色素瘤、阴性和阳性前哨淋巴结(SLN)以及伴有晚期转移的淋巴结中抑制性T淋巴细胞和耐受性树突状细胞(DCs)的存在情况、免疫抑制细胞因子(IL-10、TGFβ1和TGFβ2)的表达以及吲哚胺2,3-双加氧酶(IDO)。我们的结果表明,在疾病进展的各个阶段,黑色素瘤中均存在耐受性DCs和抑制性T淋巴细胞。它们表达转化生长因子β受体1(TGFβR1),因此易受原发性黑色素瘤特异性表达的TGFβ1和TGFβ2的影响。我们发现,IDO和白细胞介素10(IL-10)的表达随黑色素瘤进展而增加,在阳性SLN中浓度最高。我们认为,阴性SLN含有免疫抑制细胞和细胞因子,这是由于从原发性黑色素瘤部位迁移至SLN的耐受性DCs进行了预处理。在原发性黑色素瘤中,TGFβ2可能使外周DCs具有耐受性,而在淋巴结中,IDO和TGFβ1可能起主要作用。这种肿瘤相关免疫抑制机制可能会抑制对肿瘤的免疫反应,这或许可以解释抗黑色素瘤疫苗诱导的全身免疫与它们在临床上的不佳表现之间的差异。